Inotiv Past Earnings Performance

Past criteria checks 0/6

Inotiv's earnings have been declining at an average annual rate of -66.4%, while the Life Sciences industry saw earnings growing at 16.4% annually. Revenues have been growing at an average rate of 58.2% per year.

Key information

-66.4%

Earnings growth rate

-62.4%

EPS growth rate

Life Sciences Industry Growth21.5%
Revenue growth rate58.2%
Return on equity-13.3%
Net Margin-5.7%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

Inotiv (NASDAQ:NOTV) Takes On Some Risk With Its Use Of Debt

Mar 19
Inotiv (NASDAQ:NOTV) Takes On Some Risk With Its Use Of Debt

Inotiv, Inc.'s (NASDAQ:NOTV) Price Is Right But Growth Is Lacking After Shares Rocket 34%

Feb 13
Inotiv, Inc.'s (NASDAQ:NOTV) Price Is Right But Growth Is Lacking After Shares Rocket 34%

Inotiv, Inc. (NASDAQ:NOTV) Stock Rockets 61% But Many Are Still Ignoring The Company

Dec 18
Inotiv, Inc. (NASDAQ:NOTV) Stock Rockets 61% But Many Are Still Ignoring The Company

Earnings Release: Here's Why Analysts Cut Their Inotiv, Inc. (NASDAQ:NOTV) Price Target To US$12.81

Dec 13
Earnings Release: Here's Why Analysts Cut Their Inotiv, Inc. (NASDAQ:NOTV) Price Target To US$12.81

Is Inotiv (NASDAQ:NOTV) A Risky Investment?

Nov 21
Is Inotiv (NASDAQ:NOTV) A Risky Investment?

Is Inotiv (NASDAQ:NOTV) A Risky Investment?

Aug 14
Is Inotiv (NASDAQ:NOTV) A Risky Investment?

Is Inotiv (NASDAQ:NOTV) Using Debt In A Risky Way?

May 09
Is Inotiv (NASDAQ:NOTV) Using Debt In A Risky Way?

Inotiv adds 16% on settlement with U.S. over Virginia facility

Jul 18

Inotiv completes acquisition of bioanalytical company Protypia for ~$11M

Jul 07

Headwaters Capital - Inotiv: Transformation Into A Critical Full-Service Contract Research Organization

May 25

Inotiv: Leading Mid-Market CRO Ups Its Game

Feb 07

We Think Inotiv (NASDAQ:NOTV) Has A Fair Chunk Of Debt

Dec 08
We Think Inotiv (NASDAQ:NOTV) Has A Fair Chunk Of Debt

Calculating The Intrinsic Value Of Inotiv, Inc. (NASDAQ:NOTV)

Nov 17
Calculating The Intrinsic Value Of Inotiv, Inc. (NASDAQ:NOTV)

Does Inotiv (NASDAQ:NOTV) Have A Healthy Balance Sheet?

Sep 02
Does Inotiv (NASDAQ:NOTV) Have A Healthy Balance Sheet?

Inotiv reports Q2 results

May 05

Revenue & Expenses Breakdown
Beta

How Inotiv makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:NOTV Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 23585-331200
30 Sep 23572-1051270
30 Jun 23582-3401290
31 Mar 23597-3451240
31 Dec 22586-3411160
30 Sep 22548-337990
30 Jun 22427-83740
31 Mar 22277-77560
31 Dec 21156-72360
30 Sep 219011260
30 Jun 21750260
31 Mar 2168-4230
31 Dec 2065-4220
30 Sep 2060-5211
30 Jun 2059-3201
31 Mar 2055-2181
31 Dec 1948-2161
30 Sep 1944-1141
30 Jun 1938-1111
31 Mar 1933-191
31 Dec 1830081
30 Sep 1826071
30 Jun 1823061
31 Mar 1823161
31 Dec 1723161
30 Sep 1724160
30 Jun 1724-160
31 Mar 1723-260
31 Dec 1622-360
30 Sep 1620-360
30 Jun 1620-261
31 Mar 1621061
31 Dec 1522061
30 Sep 1523161
30 Jun 1524161
31 Mar 1524071
31 Dec 1424071
30 Sep 1425-171
30 Jun 1424071
31 Mar 1423061
31 Dec 1322061
30 Sep 1322160
30 Jun 1323-260
31 Mar 1325-360

Quality Earnings: NOTV is currently unprofitable.

Growing Profit Margin: NOTV is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: NOTV is unprofitable, and losses have increased over the past 5 years at a rate of 66.4% per year.

Accelerating Growth: Unable to compare NOTV's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NOTV is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-9.3%).


Return on Equity

High ROE: NOTV has a negative Return on Equity (-13.3%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.